Seneca Biopharma, Inc. (NASDAQ: SNCA) was founded in 1996, formerly known as Neuralstem, Inc. (formerly NASDAQ: CUR), changed to its current name in October 2019, headquartered in Germantown, Maryland, USA, with 7 full-time employees , Is a clinical-stage biopharmaceutical company focusing on the research and development of neurological treatments based on its proprietary human neural stem cells and small molecule compounds.
Seneca Biopharma, Inc. (SNCA):
Seneca Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the research and development of neurological therapy based on its proprietary human neuronal stem cells and small molecule compounds. The company’s stem cell-based technology can isolate and amplify human neural stem cells from various areas of the developing human brain and spinal cord to generate various physiologically relevant human neurons. Neuralstem’s patented technology can produce brain and spinal cord neural stem cells in commercial quantities, and can control the differentiation of these cells into mature, physiologically relevant human neurons and glial cells.
Neuralstem’s main product candidate is NSI-189, a chemical product that has completed a phase II clinical trial for the treatment of major depression; in addition, it is still in MCAO stroke, type 1 and type 2 diabetes-related neuropathy, radiation-induced cognition, and long-term enhancement And Angel’s syndrome.
Neuralstem’s product candidates also include NSI-566 spinal cord stem cell therapy. The Phase II clinical trial for the treatment of amyotrophic lateral sclerosis (ALS) has been completed, and the FDA has granted its orphan drug certification for ALS cell therapy. In addition to ALS, Neuralstem has It also focuses on central nervous system diseases through its NSI-566 cell therapy platform (including spinal cord injury and ischemic stroke). NSI-566 has now been approved by the FDA and the Institutional Review Board of the University of California, San Diego, to begin the I Periodic safety test.